Publications by authors named "B Meulemans"
JCO The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). Here, we report the final results of a preplanned analysis at a 10-year follow-up. In the favorable (F) ePET-negative group, the 10-year PFS rates were 98.
View Article and Find Full Text PDFIntroduction: Older patients are at higher risk of chemotherapy-induced toxicity, raising interest in less toxic anti-HER2 regimens for older persons with HER2-positive (HER2+) metastatic breast cancer (MBC).
Patients And Methods: This phase II study randomized (1:1) patients with HER2+ MBC, aged 70+ or frail 60+, to first line chemotherapy with metronomic oral cyclophosphamide (M) + Trastuzumab (T) and Pertuzumab (P) or TP alone. T-DM1 was offered in case of progression.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
April 2021
Article Synopsis
- * Conducted across 112 hospitals in nine European countries, the trial enrolled patients aged 18-70 with specific breast cancer stages and used genomic and clinical assessments to determine the treatment strategy.
- * The study aimed to explore long-term outcomes and included a random assignment for patients with conflicting risk results to evaluate the effectiveness of chemotherapy versus observation based on their risk profiles.
Article Synopsis
- - The study evaluated the effectiveness of a 70-gene signature test (MammaPrint) in predicting outcomes for women with early-stage breast cancer, comparing genomic and clinical risk factors to decide on chemotherapy treatment.
- - Out of 6693 enrolled women, 1550 were identified with high clinical risk but low genomic risk, and those not receiving chemotherapy showed a 5-year survival rate without distant metastasis of 94.7%.
- - The findings suggest that some women at high clinical risk may safely forego chemotherapy based on low genomic risk, as their survival rates were comparable to those who received treatment.
Article Synopsis
- After cancer treatment for Hodgkin's lymphoma, some survivors might have heart problems, known as cardiovascular disease.
- Researchers tried to find out how much certain treatments, like anthracyclines, vinca-alkaloids, and radiation, can increase this risk.
- They collected information from over 6000 patients and found that specific treatments were linked to heart issues, with many survivors experiencing problems like heart disease and arrhythmia.